Lymphoma, Leukemia & Myeloma Congress

Lymphoma, Leukemia & Myeloma Congress The premier forum for healthcare professionals who study and manage patients with lymphoma, myeloma

For the past sixteen years, L&M has been the premier forum on the latest advances in lymphoma and myeloma. Over forty internationally-recognized leaders in molecular biology, pathology, immunology, translational and clinical research have been involved to provide expertise and guidance on recent developments in the basic science, translational medicine and clinical trials. The Congress features an interdisciplinary approach, special lectures, debates and interactive techniques to explore the controversial, the upcoming, and the exciting in myeloma, Waldenstrom’s macroglobulinemia, chronic lymphatic leukemia, lymphoma and Hodgkin’s disease.

Happy New Year from the LL&M family! We’re grateful for this incredible community of clinicians, researchers, and learne...
01/01/2026

Happy New Year from the LL&M family!

We’re grateful for this incredible community of clinicians, researchers, and learners—and we can’t wait to continue advancing hematologic education together in 2026.

Our first event of the new year, the LL&M Winter Symposium, kicks off at the end of January. We hope to see you there as we begin another year of progress in patient care. https://hubs.ly/Q03Y9zdp0

As we reflect on another year of progress in hematologic education, we want to thank the clinicians, researchers, and pa...
12/23/2025

As we reflect on another year of progress in hematologic education, we want to thank the clinicians, researchers, and partners who make this work meaningful. Wishing you a wonderful holiday season and a bright year ahead.

The therapeutic landscape in lymphoma continues to advance, with new data informing both frontline and relapsed/refracto...
12/20/2025

The therapeutic landscape in lymphoma continues to advance, with new data informing both frontline and relapsed/refractory management across key subtypes.

At the LL&M Winter Symposium, the sessions in “Lymphoma Landscape: Emerging Data and Clinical Impact” will deliver a focused review of the most impactful updates shaping care in 2025 and beyond.

Session Highlights:
- DLBCL in 2026: Upfront Advances and New Options for Relapsed/Refractory Disease
- Current and Emerging Management of Mantle Cell Lymphoma: Toward More Personalized Care
- Advances in Indolent Lymphomas: Follicular, Waldenström’s, and Marginal Zone Updates for 2026 Practice
- Hodgkin Lymphoma in Transition: Applying 2025 Lessons to Evolving Treatment Approaches

Join us at LL&M Winter Symposium and leave with an actionable understanding of how recent data are refining therapeutic approaches across DLBCL, MCL/MZL, WM, and HL. https://hubs.ly/Q03XT4VM0

As targeted agents continue to reshape frontline CLL management, new 2025 data are refining one of the field’s most impo...
12/19/2025

As targeted agents continue to reshape frontline CLL management, new 2025 data are refining one of the field’s most important questions: How long should patients stay on therapy?

Join Neil E. Kay, MD at the LL&M Winter Symposium for a clinically grounded look at emerging evidence—from CLL17 to next-generation combinations like sonrotoclax + obinutuzumab—and what these findings mean for real-world treatment decisions.

Don’t miss this deep dive into response-adapted strategies, MRD-driven endpoints, and the evolving role of fixed-duration therapy in frontline CLL. https://hubs.ly/Q03YbxRh0

Rapid advancements in leukemia research continue to influence frontline management, induction strategies, and transplant...
12/17/2025

Rapid advancements in leukemia research continue to influence frontline management, induction strategies, and transplant decision-making.

At the LL&M Winter Symposium, the sessions in “Leukemia Landscape: Emerging Data and Clinical Impact” will provide an evidence-based overview of the most relevant updates shaping the leukemia care continuum heading into 2026.

Session Highlights:
- Frontline AML in 2026: Reassessing 7+3 and Advancing Targeted Triplet Induction Regimens
- MRD-Driven AML Care: Evolving Risk Assessment and Transplant Criteria for 2026
- Modernizing Myeloid Care: New Data in MDS and Emerging Evidence in Myeloproliferative Neoplasms
- Evolving Management of ALL: Applying 2025 Discoveries to 2026 Treatment Strategies

Join us in January and understand how new evidence may shift diagnostic and therapeutic approaches across the AML continuum. https://hubs.ly/Q03XS-HT0

The treatment landscape for multiple myeloma continues to evolve as new data redefine frontline strategies for both tran...
12/12/2025

The treatment landscape for multiple myeloma continues to evolve as new data redefine frontline strategies for both transplant-eligible and transplant-ineligible patients.

At the LL&M Winter Symposium our session block “Myeloma Landscape: Emerging Data and Clinical Impact” will offer a focused, evidence-based review of the latest developments shaping clinical practice in 2026.

Session Highlights:
- Frontline Myeloma Therapy in 2026: Transplant Decisions, Bispecifics, and CAR T in Newly Diagnosed Patients
- From 2025 Discoveries to 2026 Practice: Redefining Early Relapsed Myeloma with Next-Generation Immune Therapies
- Beyond the Triple-Class Barrier: CelMoDs, Novel Agents, and Real-World Strategies for Refractory Myeloma
- Navigating High-Risk Myeloma: Smoldering Disease, Extramedullary Spread, CNS Involvement, and Plasma Cell Leukemia

Attendees will gain a clear understanding of how 2025 data may impact treatment algorithms and therapeutic sequencing in both patient groups.

Stay current on the evidence shaping next-generation myeloma care. Secure your spot today: https://hubs.ly/Q03XSW9J0

Rachid Baz, MD (Moffitt Cancer Center) joins the LL&M Winter Symposium to discuss one of the fastest-moving areas in mul...
12/11/2025

Rachid Baz, MD (Moffitt Cancer Center) joins the LL&M Winter Symposium to discuss one of the fastest-moving areas in multiple myeloma:
the evolving frontline landscape for transplant-ineligible patients.

With bispecific antibodies and CAR T-cell therapy moving earlier in the disease course, Dr. Baz will break down the pivotal trials shaping what frontline care may look like in 2026 and beyond, including:

- IMMUNOPLANT – 100% MRD-negative conversion with short-course immune consolidation
- LINKER-MM4 – Early evidence for immunotherapy-only induction
- IFM2021-01 Teclille - 100% ORR and 78% VGPR in elderly patients with NDMM which compares favorably with quad therapy

Join Dr. Baz for a practical, data-driven look at how bispecifics, CAR T, and immune-based strategies could redefine treatment for TIE myeloma.

January 30 – February 1, 2026
The Ritz-Carlton, Amelia Island
Register today: https://hubs.ly/Q03XSjR30

12/11/2025

At the LL&M Winter Symposium, our faculty brings you the essential takeaways from the largest hematology-oncology conferences across the globe—curated, analyzed, and translated into practical guidance for your 2026 practice.

Stay ahead of the curve. Start the year with evidence-driven updates and expert-led discussions you can put into action. Learn more here: https://hubs.ly/Q03XTmzc0

Advances in CLL are accelerating, and staying current with the latest data is essential for informed clinical decision-m...
12/09/2025

Advances in CLL are accelerating, and staying current with the latest data is essential for informed clinical decision-making.

At the LL&M Winter Symposium, our session block “CLL Landscape: Emerging Data and Clinical Impact” will provide a concise, evidence-based review of the most relevant developments shaping practice in 2026.

What You’ll Learn:

Optimizing BTKi + BCL2i Combinations in CLL: Upfront Strategies, Resistance, and Mutation Management

Continuous vs Fixed-Duration Therapy in CLL: Lessons From 2025 and Evolving Sequencing Approaches

Beyond Covalent BTK Inhibitors: BTK Degraders and Next-Generation Options After BTKi Failure

High-Risk CLL and Richter Transformation: Positioning Bispecifics and CAR T for 2026 and Beyond

Join us on Amelia Island and leave with a clearer understanding of how emerging evidence may refine therapeutic strategies in the year ahead.

https://hubs.ly/Q03XwT1f0

Fresh from the scientific stage and straight into the LL&M Winter Symposium.We’re honored to welcome Dr. Gail Roboz, int...
11/30/2025

Fresh from the scientific stage and straight into the LL&M Winter Symposium.

We’re honored to welcome Dr. Gail Roboz, internationally recognized AML expert and Co-Chair of the LL&M Winter Symposium, as she brings her latest data directly to our community. Following her oral presentation during ASH 2025, Dr. Roboz will share new results from her team’s Phase 1b study evaluating the ziftomenib + venetoclax + azacitidine triplet in newly diagnosed NPM1-mutated AML.

Her session at the LL&M Winter Symposium, Updates in Targeted Triplet Induction Regimens in AML for 2026 Practice, will offer a rare opportunity to hear how emerging triplet strategies may reshape induction approaches, deepen responses, and influence frontline decision-making for the year ahead.

If you manage AML in practice, this is a session you won’t want to miss.
Join us in January to hear where the field is heading—directly from one of its most influential voices.

Learn more: https://hubs.ly/Q03V-0zl0

At the LL&M Winter Symposium, we believe that meaningful education starts with voices who understand the realities of c...
11/26/2025

At the LL&M Winter Symposium, we believe that meaningful education starts with voices who understand the realities of clinical practice.

This year, we're proud to spotlight our Associate Chairs—leaders from key local institutions whose on-the-ground expertise enriches every discussion. Their insights help guide the program, shape session dialogue, and ensure that new data is framed through the lens of what clinicians truly encounter day to day.

The Associate Chairs join our Co-Chairs in shaping a program that reflects the full spectrum of hematology care. Their combined expertise ensures the LL&M Winter Symposium offers a comprehensive, practice-ready agenda grounded in both innovation and real-world clinical needs.

Learn more: https://hubs.ly/Q03V-bNy0

Behind every impactful meeting is strong scientific leadership.At the LL&M Winter Symposium, our program is shaped by so...
11/24/2025

Behind every impactful meeting is strong scientific leadership.

At the LL&M Winter Symposium, our program is shaped by some of the most respected voices in hematologic malignancies. Experts who live and breathe the science, and who are committed to helping clinicians navigate an ever-changing landscape.

In 2026, our leadership will go beyond the headlines to interpret the data that matters most. Highlighting what’s promising, what’s practice-changing, and how new evidence fits into real-world care.

Through focused sessions and interactive discussions, they’ll guide you through the latest breakthroughs, evolving standards, and what’s on the horizon for the field.

Join us in the new year as we translate cutting-edge research into meaningful impact for patients everywhere. https://hubs.ly/Q03VHGzx0

Address

811 W 7th Avenue
New York, NY

Website

Alerts

Be the first to know and let us send you an email when Lymphoma, Leukemia & Myeloma Congress posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Our Story

For the past twenty years, L&M has been the premier forum on the latest advances in lymphoma and myeloma. Over forty internationally-recognized leaders in molecular biology, pathology, immunology, translational and clinical research have been involved to provide expertise and guidance on recent developments in the basic science, translational medicine and clinical trials. The Congress features an interdisciplinary approach, special lectures, debates and interactive techniques to explore the controversial, the upcoming, and the exciting in myeloma, Waldenstrom’s macroglobulinemia, chronic lymphatic leukemia, lymphoma and Hodgkin’s disease.